Researchers from the Mayo Clinic have found that PET/MR can help guide post- neoadjuvant therapy (NAT) pancreatic cancer treatment decisions to optimize treatment decisions and long-term outcomes6. The study, recently published in the American Journal of Roentgenology, assessed pathologic tumor response to emergent pancreatic cancer therapies and predicted overall survival using PET/MR and CT data.
The authors wrote that PET/MR provides a non-invasive selection tool to help clinicians decide if surgery will benefit the patient, and if alternate treatment regimens could optimize a patient’s chances for favorable long-term outcomes. They concluded that PET/ MR’s potential in pancreatic cancer provides clinicians with a clearer picture of the therapies’ efficacy and can guide next steps, potentially allowing specialists to tailor care to each patient’s disease profile.
Reference
6. Panda A, Garg I, Truty MJ, et al. Borderline Resectable and Locally Advanced Pancreas Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Neoadjuvant Therapy Pathologic Response and Prediction of Survival. AJR Am J Roentgenol. 2020 Oct 21. Available at: https://www.ajronline.org/doi/pdf/10.2214/AJR.20.24567.
